SSG
MDGL icon

Summit Securities Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Summit Securities Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$79.5K Buy
+148
New +$75.8K 0.01% 478
2025
Q2 		– Sell
-100
Closed -$33.1K – 1283
2025
Q1 		$33.1K Buy
+100
New +$32.9K 0.01% 388
2013
Q4 		– Sell
-94
Closed -$21K – 567
2013
Q3 		$21K Buy
94
+62
+194% +$13.2K 0.01% 228
2013
Q2 		$6K Buy
+32
New +$8.34K ﹤0.01% 370

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Summit Securities Group's MDGL Position: Q2 2026 in Review

Summit Securities Group opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 148 shares worth $79.5K. The stake represents 0.01% of the portfolio and ranks #478 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in MDGL as recently as Q1 2025.

Summit Securities Group first reported a position in MDGL in Q2 2013 and has held it in 4 quarters since. 415 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Summit Securities Group held 148 shares of Madrigal Pharmaceuticals worth $79.5K as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Summit Securities Group position in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.01% of Summit Securities Group's portfolio in Q2 2026, its #478 holding.
  • Summit Securities Group first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 4 quarters since.
  • 415 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.